AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02753647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02753647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02753647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT02753647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02753647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Study NCT03731117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period
Study NCT00589108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma Knee System
Description: Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
Study NCT02566460 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Resuscitation
Description: First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
Study NCT02566460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resuscitation
Description: First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
Study NCT01905631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aurstat Anti-Itch Hydrogel (Aurstat)
Description: Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
Study NCT02008552 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Sampling of blood
Description: Sampling of blood was taken and analyse to research factor genetic
Study NCT00840762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VircoType HIV-1 genotypic interpretation
Description: VircoType HIV-1 genotypic interpretation
Study NCT00840762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local Expert Review of HIV Genotypic resistance testing
Description: Local Expert Review of HIV Genotypic resistance testing
Study NCT00363428 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise intervention
Description: life style
Study NCT00363428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: life style
Study NCT00363428 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: smoking cessation intervention
Description: Life style
Study NCT00363428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation intervention
Description: Life style
Study NCT00363428 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: counseling intervention
Description: life style
Study NCT00363428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: life style
Study NCT00363428 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: educational intervention
Description: life style
Study NCT00363428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: life style
Study NCT00363428 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional surgery
Description: life style
Study NCT00363428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: life style
Study NCT00363428 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: pulmonary complications management/prevention
Description: life style
Study NCT00363428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary complications management/prevention
Description: life style
Study NCT03965507 — intervention group
Intervention type: OTHER
Intervention: Evaluation of the prevalence of sacroiliac joint dysfunction in lumbar disc herniation
Study NCT01884909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate ER Tablet 200 mg
Description: 1 \* 200 mg tablet per day
Study NCT01884909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate ER Tablet 200 mg
Description: 1 \* 200 mg tablet per day
Study NCT01884909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 'TOPROL-XL®' ER Tablets 200 mg
Description: 1 \* 200 mg tablet per day
Study NCT01884909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 'TOPROL-XL®' ER Tablets 200 mg
Description: 1 \* 200 mg tablet per day
Study NCT03669952 — intervention group
Intervention type: OTHER
Intervention: None intervention
Description: No interventions are realized, only observational study
Study NCT03934242 — intervention group
Intervention type: OTHER
Intervention: Questionnaire on new born's bedding
Description: Questionnaire on new born's bedding (Child's position in the bed : dorsal, ventral or lateral, presence of pillow or stuffed in bed, presence of coverage and presence of the bed sharing) at two times (during hospitalisation and one month later)
Study NCT02190968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Depression Care
Description: Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR\*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
Study NCT02190968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Depression Care
Description: Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR\*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
Study NCT00589108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray
Description: Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
Study NCT00589108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray
Description: Sigma Pressfit Condylar Posterior Cruciate Substituting System (fixed bearing with an all polyethylene tray)
Study NCT00839488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: famotidine 20 mg iv
Description: famotidine 20 mg q12h
Study NCT01138202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: LPV/r 400/100 mg BID + 2 NRTI for arm 1 (total 48 weeks) LPV/r 600/150 mg BID + 2 NRTI for arm 2 (total 48 weeks)
Study NCT01151124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX0E03 neural stem cells
Description: Single administration by surgical delivery to the damaged area of the brain
Study NCT02502786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-GD2 antibody
Study NCT02502786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Study NCT03685331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Combination of palbociclib, olaparib, and fulvestrant.
Study NCT02190968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Mood Balance
Description: Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
Study NCT01810575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WC3036-11F/Alprostadil in Vehicle 2.5%
Description: 330 mcg alprostadil in 2.5% vehicle
Study NCT01810575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3036-12F/Alprostadil in Vehicle 0.5%
Description: 330 mcg alprostadil in 0.5% vehicle
Study NCT01810575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WC3036-13P/Vehicle Only 0.5%
Description: 100 mg cream vehicle 0.5%.
Study NCT03685331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Combination of palbociclib, olaparib, and fulvestrant.
Study NCT03685331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Combination of palbociclib, olaparib, and fulvestrant.
Study NCT01285765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCHOP21
Description: Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
Study NCT01285765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RCHOP21
Description: Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
Study NCT02920268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance and yoga intervention
Study NCT00071812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
Study NCT00071812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Description: Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
Study NCT00071812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 4 mg/kg
Description: Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
Study NCT00071812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
Study NCT02534792 — intervention group
Intervention type: OTHER
Intervention: Revalvulation
Study NCT01296724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measure of intravesical pressure
Description: For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
Study NCT01296724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measure of intravesical pressure
Description: For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
Study NCT03913143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sepofarsen
Description: RNA antisense oligonucleotide for intravitreal injection
Study NCT03913143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sepofarsen
Description: RNA antisense oligonucleotide for intravitreal injection
Study NCT03913143 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham-Procedure (no experimental drug administered)
Study NCT03344185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Diet
Description: This intervention consisted of three low GI meals.
Study NCT03344185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Glycaemic Diet
Description: This intervention consisted of three meals, all with a high GI value.
Study NCT04527081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19
Description: 2.0 mg of AG0302-COVID19 twice at 2-week intervals
Study NCT01187615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed
Description: In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.
Study NCT01187615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed
Description: In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
Study NCT04527081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19
Description: 2.0 mg of AG0302-COVID19 twice at 4-week intervals
Study NCT04491773 — intervention group
Intervention type: DRUG
Intervention: Tadalafil 20 MG
Description: To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, for more than 6 months.
Study NCT01202344 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Additional x-ray images
Description: Approximately 3 additional x-ray images following angioplasty (within 1 hour)
Study NCT01157065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-78898A
Description: Investigational treatment
Study NCT01157065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Anti-vascular endothelial growth factor (VEGF) treatment
Study NCT04527081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19
Description: 2.0 mg of AG0302-COVID19 three times at 2-week intervals
Study NCT01982422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Food, Nutrient-Dense Dietary Intervention
Description: The dietary intervention will be a whole food, nutrient-dense diet which restricts processed foods high in food additives while optimizing micronutrient intake.
Study NCT01982422 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Normal standard-of-care for pregnancy.
Study NCT01973634 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)
Description: Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)
Study NCT01973634 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
Description: Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
Study NCT01973634 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
Description: Minimal surgical margin \< 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
Study NCT01973634 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
Description: Minimal surgical margin \< 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
Study NCT01015846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Redcord (sling exercise) and traditional exercise
Study NCT01015846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stability exercise
Description: Traditional core stability exercise
Study NCT00256217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg. oral every day for 2 - 4 weeks
Study NCT02333578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma Treatment
Description: This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
Study NCT03662100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC
Study NCT03662100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC
Study NCT03662100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-injector (AI)
Description: AI to administer LY3074828
Study NCT03662100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled syringe (PFS)
Description: PFS to administer LY3074828
Study NCT04216862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Different type of exercises for treatment of Forward Head Posture
Study NCT04216862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Different type of exercises for treatment of Forward Head Posture
Study NCT01257204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablets, oral, 0 mg, once daily, for 24 weeks
Study NCT01257204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
Study NCT01257204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
Study NCT01257204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a
Description: Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
Study NCT01257204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
Study NCT01257204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
Study NCT02666235 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischaemic conditioning
Description: Intermittent inflation of an arm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a drawn curtain. The clinical team and researchers will be masked to the intervention type.
Study NCT02666235 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arm cuff placement, no inflation;
Description: Sham procedure involving arm cuff placement, no inflation: A blood pressure cuff will be placed on the arm for 40 minutes. The cuff will not be inflated. The patient will be in bed behind a curtain on the cardiology ward. The curtain will obscure the patient from the attending cardiology team. The clinical team and researchers will be masked to the intervention type.
Study NCT01836484 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion-weighted MRI
Study NCT01836484 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorodeoxyglucose-18-PET/CT